Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2017

Open Access 01-12-2017 | Research

CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer

Authors: Jiahui Si, Panpan Zhang, Dan Tian, Xing Wang, Yuanyuan Ma, Jianzhi Zhang, Lu Wang, Yue Yang

Published in: World Journal of Surgical Oncology | Issue 1/2017

Login to get access

Abstract

Background

Considering neoadjuvant chemotherapy (NAC) prior to surgery could shrink and reduce the primary tumor and distant micro-metastases to reduce the high relapses rates, NAC has been an accepted therapeutic management for patients with non-small cell lung cancer (NSCLC). CMTM1_v17 is highly expressed in human testis tissues and solid tumor tissues but relatively low expression was obtained in the corresponding normal tissues. This study aims to investigate the significance of CMTM1_v17 in NSCLC and its association with platinum-based NAC efficacy.

Methods

31 pairs of tumor tissues before and after NAC and 78 resected tumor tissues after NAC were utilized for immunohistochemistry (IHC) staining of CMTM1_v17 protein. The correlation between CMTM1_v17 expression and chemotherapy efficacy was analyzed. The prognostic value of CMTM1_v17 index for disease-free survival (DFS) and overall survival (OS) was analyzed using Kaplan-Meier survival and multivariable Cox regression.

Results

CMTM1_v17 expression was related to treatment effect and outcome in tumor tissues after NAC not before NAC from 31 cases of NSCLC. We identified that high CMTM1_v17 expression was associated with low objective remission rate (ORR) (P = 0.008) and poor prognosis (the median OS: 35.1 months vs 65.6 months, P = 0.0045; the median DFS: 17.27 months vs 35.54 months, P = 0.0207) in the 31 patients. Next, we detected CMTM1_v17 expression to confirm correlation between this protein status and clinical characteristics in 78 NSCLC patients with NAC treatment. The upregulation of CMTM1_v17 had a higher SD rate (P = 0.007) and worse outcome (the median OS: 41.0 months vs 80.6 months, P = 0.0028; the median DFS: 33.4 vs 64.8 months, P = 0.0032). COX multivariate analysis indicated that CMTM1_v17 is an independent prognostic risk factor on patients who have received NAC (OS: HR = 3.642, P = 0.002; DFS:HR = 3.094, P = 0.002).

Conclusions

CMTM1_v17 expression is significantly associated with chemoresistance and poor prognosis of the early stage NSCLC patients who have received NAC.
Literature
1.
2.
3.
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging C, Participating I. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2:706–14.CrossRefPubMed
4.
Boudaya MS, Smadhi H, Marghli A, Charmiti F, Ouerghi S, Mohamed J, Brahem E, Smati B, Mestiri T, Kilani T. What outcome after the prescription of neoadjuvant chemotherapy in lung cancer? Asian Cardiovasc Thorac Ann. 2013;21:432–6.CrossRefPubMed
5.
Lv C, Ma Y, Wu N, Yan S, Zheng Q, Sun Y, Li S, Fang J, Yang Y. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer. World J Surg Oncol. 2013;11:76.CrossRefPubMedPubMedCentral
6.
Decaluwe H, De Leyn P, Vansteenkiste J, Dooms C, Van Raemdonck D, Nafteux P, Coosemans W, Lerut T. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg. 2009;36:433–9.CrossRefPubMed
7.
Meacci E, Cesario A, Cusumano G, Lococo F, D'Angelillo R, Dall'armi V, Margaritora S, Granone P. Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: the microscopic seed of doubt. Eur J Cardiothorac Surg. 2011;40:656–63.PubMed
8.
Toyooka S, Kiura K, Takemoto M, Oto T, Takigawa N, Fujiwara T, Miyoshi S, Date H. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg. 2012;14:565–9.CrossRefPubMedPubMedCentral
9.
Wang L, Wu C, Zheng Y, Qiu X, Wang L, Fan H, Han W, Lv B, Wang Y, Zhu X, et al. Molecular cloning and characterization of chemokine-like factor super family member 1 (CKLFSF1), a novel human gene with at least 23 alternative splicing isoforms in testis tissue. Int J Biochem Cell Biol. 2004;36:1492–501.CrossRefPubMed
10.
Zhu BM, Li T, Zhou YL, Song QS, Wang L. [CMTM1-v17, a new potential corepressor of androgen receptor]. Beijing Da Xue Xue Bao. 2007;39:388–93.PubMed
11.
Wang J, Zhang G, Zhang Y, Luo Y, Song Q, Qiu X, Mo X, Wang L. CMTM1_v17 is a novel potential therapeutic target in breast cancer. Oncol Rep. 2014;32:1829–36.PubMed
12.
13.
Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001;18:1059–68.CrossRefPubMed
14.
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.CrossRefPubMed
15.
Kelman AD, Peresie HJ. Mode of DNA binding of cis-platinum(II) antitumor drugs: a base sequence-dependent mechanism is proposed. Cancer Treat Rep. 1979;63:1445–52.PubMed
16.
Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res. 2001;7:775–83.PubMed
17.
Gadducci A, Cosio S, Muraca S, Genazzani AR. Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications. Eur J Gynaecol Oncol. 2002;23:390–6.PubMed
18.
Han JY, Hong EK, Choi BG, Park JN, Kim KW, Kang JH, Jin JY, Park SY, Hong YS, Lee KS. Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer. Med Oncol. 2003;20:355–62.CrossRefPubMed
19.
Janson V, Johansson A, Grankvist K. Resistance to caspase-8 and −9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance. Cell Death Dis. 2010;1:e78.CrossRefPubMedPubMedCentral
20.
Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW, Rocco JW. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2009;15:1645–54.CrossRefPubMedPubMedCentral
21.
Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem. 2000;275:35778–85.CrossRefPubMed
22.
23.
Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 2000;275:39435–43.CrossRefPubMed
24.
Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, Cheng AL. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol. 2002;63:1423–30.CrossRefPubMed
25.
Galenkamp KM, Carriba P, Urresti J, Planells-Ferrer L, Coccia E, Lopez-Soriano J, Barneda-Zahonero B, Moubarak RS, Segura MF, Comella JX. TNFalpha sensitizes neuroblastoma cells to FasL-, cisplatin- and etoposide-induced cell death by NF-kappaB-mediated expression of Fas. Mol Cancer. 2015;14:62.CrossRefPubMedPubMedCentral
26.
Zhi X, Tao J, Xiang G, Cao H, Liu Z, Yang K, Lv C, Ni S. APRIL induces cisplatin resistance in gastric cancer cells via activation of the NF-kappaB pathway. Cell Physiol Biochem. 2015;35:571–85.CrossRefPubMed
27.
Alamgeer M, Ganju V, Kumar B, Fox J, Hart S, White M, Harris M, Stuckey J, Prodanovic Z, Schneider-Kolsky ME, Watkins DN. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res. 2014;16:R44.CrossRefPubMedPubMedCentral
28.
Akunuru S, James Zhai Q, Zheng Y. Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis. 2012;3:e352.CrossRefPubMedPubMedCentral
29.
Korkaya H, Liu S, Wicha MS. Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res. 2011;17:6125–9.CrossRefPubMedPubMedCentral
30.
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117:3988–4002.CrossRefPubMedPubMedCentral
Metadata
Title
CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer
Authors
Jiahui Si
Panpan Zhang
Dan Tian
Xing Wang
Yuanyuan Ma
Jianzhi Zhang
Lu Wang
Yue Yang
Publication date
01-12-2017
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2017
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/s12957-016-1094-z

Other articles of this Issue 1/2017

World Journal of Surgical Oncology 1/2017 Go to the issue

Research

Identification and interaction analysis of key genes and microRNAs in hepatocellular carcinoma by bioinformatics analysis

Research

Stage 1 embryonal rhabdomyosarcoma of the female genital tract: a retrospective clinical study of nine cases

Research

Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients

Research

Study on expression of CDH4 in lung cancer

Research

Long noncoding RNA expression profiles in sub-lethal heat-treated hepatoma carcinoma cells

Research

Radiation dose affected by mammographic composition and breast size: first application of a radiation dose management system for full-field digital mammography in Korean women